The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Open accessAbstract
OBJECTIVES: To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research (EUSTAR) cohort and using a nested case-control design. METHODS: Inclusion criteria were fulfilment of American College of Rheumatology classification criteria for SSc, treatment with RTX and availability of follow-up data. RTX-treated patients were matched with control patients from the EUSTAR database not treated with RTX. Matching parameters for skin/lung fibrosis were the modified Rodnan Skin Score (mRSS), forced vital capacity (FVC), follow-up duration, scleroderma subtype, disease duration and immunosuppressive co-treatment. The primary analysis was mRSS change from baseline to follow-up in the RTX group compared with the control group. Secondary analyses included change of FVC and safety measures. RESULTS: 63 patients treated with RTX were included in the analysis. The case-control analysis in patients with severe diffuse SSc showed that mRSS changes were larger in the RTX group versus matched controls (N=25; -24.0±5.2% vs -7.7±4.3%; p=0.03). Moreover, in RTX-treated patients, the mean mRSS was significantly reduced at follow-up compared with baseline (26.6±1.4 vs 20.3±1.8; p=0.0001). In addition, in patients with interstitial lung disease, RTX prevented significantly the further decline of FVC compared with matched controls (N=9; 0.4±4.4% vs -7.7±3.6%; p=0.02). Safety measures showed a good profile consistent with previous studies in autoimmune rheumatic diseases. CONCLUSIONS: The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis, supporting the therapeutic concept of B cell inhibition in SSc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Walker, U. A., Tyndall, A., Czirják, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Müller-Ladner, U., Bocelli-Tyndall, C., & Matucci-Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 929
Self-citationClements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
Systemic and cell type-specific gene expression patterns in scleroderma skin
Whitfield, M. L., Finlay, D. R., Murray, J. I., Troyanskaya, O. G., Chi, J.-T., Pergamenschikov, A., McCalmont, T. H., Brown, P. O., Botstein, D., & Connolly, M. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635114100 · Cited by 409
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Daoussis, D., Liossis, S.-N. C., Tsamandas, A. C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Karampetsou, M., Yiannopoulos, G., & Andonopoulos, A. P. (2010) · Rheumatology · doi:10.1093/rheumatology/kep093 · Cited by 394
Tedder, T. F., Inaoki, M., & Sato, S. (1997) · Immunity · doi:10.1016/s1074-7613(00)80418-5 · Cited by 383
Cited by
Systemic sclerosis-associated interstitial lung disease
Perelas, A., Silver, R. M., Arrossi, A. V., & Highland, K. B. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30480-1 · Cited by 422
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Doyle, T. J., Dhillon, N., Madan, R., Cabral, F., Fletcher, E. A., Koontz, D. C., Aggarwal, R., Osorio, J. C., Rosas, I. O., Oddis, C. V., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170541 · Cited by 102
Metadata
- Authors
- Jordan, S., Distler, J. H. W., Maurer, B., Huscher, D., van Laar, J. M., Allanore, Y., Distler, O., Airo, P., Sancho, J. J. A., Ananjeva, L., Ancuta, C. M., Aringer, M., Balbir-Gurman, A., Cantatore, F. P., Caramaschi, P., Chatelus, E., Codullo, V., Farge-Bancel, D., Foti, R., Gabrielli, A., Henes, J., Herrgott, I., Iannone, F., Ingegnoli, F., Loyo, E., Matucci-Cerinić, M., Abdel Atty Mohamed, W. A., Müller-Ladner, U., Palm, Ø., Popa, S., Riemekasten, G., Rednic, S., Rosato, E., Saracco, M., Scheja, A., Smith, V., Mihai, C., Szucs, G., Tomšič, M., Valentini, G., Walker, U. A., Westhovens, R., Yavuz, S. K., & Zenone, T.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 74
- Issue
- 6
- Pages
- 1188-1194
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2095975942
- Cited by
- 434
- References
- 39
- FWCI
- 29.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-204522
- The paper
- Jordan, S., Distler, J. H. W., Maurer, B., Huscher, D., van Laar, J. M., Allanore, Y., Distler, O., Airo, P., Sancho, J. J. A., Ananjeva, L., Ancuta, C. M., Aringer, M., Balbir-Gurman, A., Cantatore, F. P., Caramaschi, P., Chatelus, E., Codullo, V., Farge-Bancel, D., Foti, R., . . . Zenone, T. (2015). Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-204522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.